The Anti-hepatitis B Virus Activity of Boehmeria nivea Extract in HBV-viremia SCID Mice by Chang, Jia-Ming et al.
Advance Access Publication 7 January 2008 eCAM 2010;7(2)189–195
doi:10.1093/ecam/nem180
Original Article
The Anti-hepatitis B Virus Activity of Boehmeria nivea Extract
in HBV-viremia SCID Mice
Jia-Ming Chang
1, Kai-Ling Huang
2, Thomas Ta-Tung Yuan
1, Yiu-Kay Lai
2,3 and
Le-Mei Hung
1
1Division of Research and Development, Development Center for Biotechnology, Xizhi City, Taipei County,
Taiwan 221,
2Department of Life Sciences and Institute of Biotechnology, National Tsing Hua University, Hsinchu,
Taiwan 30013 and
3Department of Bioresources, Da-Yeh University, Changhua, Taiwan 515, R.O.C.
Boehmeria nivea extract (BNE) is widely used in southern Taiwan as a folk medicine for hepato-
protection and hepatitis treatment. In previous studies, we demonstrated that BNE could
reduce the supernatant hepatitis B virus (HBV) DNA in HBV-producing HepG2 2.2.15 cells.
In the present study, we established an animal model of HBV viremia and used it to validate
the efficacy of BNE in vivo. In this animal model, serum HBV DNA and HBsAg were elevated
in accordance with tumor growth. To evaluate the anti-HBV activity of BNE, HBV-viremia
mice were built up after one subcutaneous inoculation of HepG2 2.2.15 tumor cells in severe
combined immunodeficiency mice over 13 days. The levels of serum HBV DNA were elevated
around 10
5–10
6 copies per milliliter. Both oral and intraperitoneal administration of BNE were
effective at inhibiting the production of HBsAg and HBV DNA, whereas tumor growth was
not affected by all test articles. Intraperitoneal administration of BNE appeared to have greater
potential to inhibit serum HBV DNA levels compared with oral administration under the same
dosage. Notably, reduced natural killer cell activity was also observed after high dosage of
BNE administration, and this correlated with reduced serum HBV DNA. In conclusion, BNE
exhibited potential anti-HBV activity in an animal model of HBV viremia.
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Introduction
Hepatitis B is caused by hepatitis B virus (HBV) infection
that is common in Asia, Africa and the Middle East.
Approximately 2–5% of HBV-infected people have the
potential to develop a chronic infection, and HBV
carriers have elevated risk for the development of
cirrhosis and hepatocellular carcinoma (1). HBV is an
enveloped DNA virus of the hepadnaviridae family that
contains 3.2kb partially double-stranded circular
genome. HBV is replicated through core protein encapsi-
dation of the viral pre-genomic RNA (pgRNA) that is
subsequently converted to double stranded (dsDNA) by
viral reverse transcriptase/polymerase to form a nucleo-
capsid. The nucleocapsid is then enveloped by the viral
surface protein (2). Currently, interferon-a (acting as an
immunomodulator) and the nucleoside analogs lamivu-
dine (3TC), adefovir and entecavir (acting as viral reverse
transcriptase/polymerase inhibitors) are drugs approved
for treatment of chronic hepatitis B (3,4). Despite the
synergistic effect of combination therapy of these drugs
for the improvement of INF-a unresponsiveness or drug
resistance in HBV-infected patients, the drug-resistant
HBV variants remain a major problem in hepatitis B
management (5–7). Therefore, sustained and diversified
strategies for viral suppression are crucial to reduce
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properly cited.hepatic inflammation, progression of liver fibrosis, and
hepatoma (8).
Approaches for the treatment of chronic HBV infection
have been in development for the past decade, and when
combined with a number of anti-viral drugs these
treatments may have potential to improve the effective-
ness of anti-HBV therapy. Chinese medicinal herbs have
been used for centuries to treat liver disease (9). Recently,
the flavonoid ellagic acid from woody dicotyledonous
plants has been found to block hepatitis B e antigen
(HBeAg) secretion either in an HBV-infected cell line or
in HBeAg transgenic mice (10). In addition, sesquiterpene
lactones from Senecio species suppress the expression
of hepatitis B s antigen (HBsAg) and HBeAg (11), and
an ethanol extract of Polygonum cuspidatum inhibits
HBV production in an HBV-producing cell line (12). An
extract of the genus Phyllanthus has a positive effect on
the clearance of HBsAg in clinical trials conducted on
chronic HBV infections, and the extract has a synergistic
effect when administered with IFN-a (9). Our previous
studies demonstrated that crude root extract of
Boehmeria nivea had anti-HBV activity via the inhibition
of HBV production in HepG2 2.2.15 cells (13). This
B. nivea extract (BNE) suppressed the production of
infectious virus but not intracellular HBV DNA replica-
tion, and its anti-HBV mechanism appears to differ from
that of the nucleoside analogs. Thus, it is conceivable
that BNE might work synergistically with other anti-viral
compounds for the treatment of HBV infection.
HBV replicates through an RNA intermediate by its
reverse transcriptase/polymerase. The viral reverse tran-
scriptase/polymerase lacks a proofreading function, how-
ever, thus leading to the formation of drug-resistant
mutants that in turn cause serious problems with current
management of hepatitis B infection (14). Therefore,
effective treatment strategies with different pharmacolo-
gical modes are urgently needed to lessen the enormous
burden of viral hepatitis on health care worldwide.
A major obstacle to the development of anti-HBV
drugs is the lack of an efficient in vitro cell model or an
easy-to-use conventional animal model that is promising
for natural viral infection and replication (15). Avail-
ability of laboratory animal models of HBV infection is
imperative for the development of effective methods to
treat these diseases. One of the few animal models for
HBV infection is the chimpanzee, which is extensively
used to evaluate the safety and immunogenicity of HBV
vaccines (16). However, the limited availability and the
high cost of these primates severely restrict their use
for such purposes. Investigators have attempted to estab-
lish conventional animal models to mimic human HBV
replication in rats (17), nude mice (18) and transgenic
mice (19). Other animal models, such as woodchuck
hepatitis virus in woodchuck and duck hepatitis virus in
duck, have also been developed to assess anti-viral drugs
(20). However, testing of anti-viral agents, including
nucleoside analogs, in these non-human HBV models
may produce aberrant results as a consequence of virus-
specific differential susceptibility of the viral polymerase
to these agents (21). Thus, establishment of a rapid,
convenient and less expensive animal model would
greatly facilitate this area of research. In this study, we
established an HBV-viremia animal model and studied
the efficacy of BNE in vivo.
Subjects and Methods
Experimental Animals and Cell Culture
Male severe combined immunodeficiency (SCID) mice
4–6 weeks of age, C.B17/icr-scid, were purchased from
the experimental animal center of National Taiwan
University (Taipei, Taiwan, R.O.C.). The human hepa-
toma HepG2 cell line was purchased from American
Type Culture Center (ATCC, USA), and the HepG2
2.2.15 cell line was kindly given by Dr Ho, MS
(Academia Sinica, Taipei, Taiwan, R.O.C.). These
hepatoma cells were maintained in minimum essential
medium (Gibco, USA) containing 10% fetal bovine
serum (Hyclone, USA), 1.5gl
1 sodium bicarbonate,
0.1mM non-essential amino acids, 1.0mM sodium
pyruvate, and 100Uml
1 penicillin G (Gibco, USA)
and 100mgml
1 streptomycin (Gibco, USA). A final
concentration of 200mgml
1 G418 (Gibco, USA) was
included in the medium for the maintenance of HepG2
2.2.15 cells. YAC-1 cells (ATCC, USA) for the natural
killer (NK) cell activity assay were cultured in RPMI
1640 medium containing 2mM L-glutamine, 1.5gl
1
sodium bicarbonate, 10mM HEPES and 10% fetal
bovine serum.
Anti-HBV Drugs and BNE
To prepare the B. nivea (L.) Gaudich plant extract
(i.e. BNE) utilized in our experiments, the roots of the
plants were collected and dried (13). Briefly, 100g of the
dried roots was cut into pieces 0.5cm in length before
boiling in 1l of 20% ethanol under boiling reflux for 3h.
The decoction was filtered through a 0.22mm filter
and lyophilized into powder. 3TC was purchased from
GlaxoSmithKline (Holland).
Establishment of an HBV-Viremia Animal Model
To establish HBV-viremia animals, the 20 experimental
SCID mice were divided into three groups: HepG2 group
(n=8), HepG2 2.2.15 group (n=8) and one vehicle
control group (n=4). The SCID mice were inoculated
with 10
7 HepG2 or HepG2 2.2.15 cells in 100ml
phosphate-buffered saline (PBS) into the flank subcuta-
neously. The control group was inoculated likewise with
190 Anti-HBV activity of B. nivea extract in vivoPBS. Tumors were measured using a caliper, and tumor
weight was calculated with the equation: tumor weight
(in mg)=length (in mm)width (in mm
2)/2 (22). On
post-inoculation Day 0 and Day 14, blood was collected
by retro-orbital sampling. On Day 28, the mice were
sacrificed and blood was collected directly from the heart.
Serum HBsAg and HBV DNA were analyzed as
described subsequently.
Determination of Serum Alanine Aminotransferase
(ALT) and Serum HBsAg
A blood sample was withdrawn from tumor-bearing ani-
mals at the indicated times (Days 0, 14 and 28), and liver
function was evaluated based on the levels of ALT. ALT
activity was determined with the DTSC II Module
detection system (Johnson-Johnson Co., USA) using
the Vitros ALT/SGPT kit (Johnson-Johnson) as per the
user manual. HBsAg levels in mouse serum were deter-
mined semi-quantitatively by enzyme-linked immunosor-
bent assay (ELISA; General Biologicals Corp., Taiwan,
R.O.C.) according to the user manual. The cutoff
value was calculated by the formula: cutoff value=
ODnagative control+0.025. An OD450 value higher than the
cutoff value implies an HBV-positive result.
Determination of HBV DNA by the Quantitative
Real-time Polymerase Chain Reaction (PCR)
Blood (500ml) was withdrawn from test animals at the
indicated times (Days 13 and 24). Blood was allowed to
clot for 30min and then centrifuged at 800g for 15min at
room temperature. Serum was collected and stored at
70C prior to analysis of HBsAg and HBV DNA.
Serum HBV DNA was extracted by a QIAamp DNA
Blood Mini kit (Qiagen, USA). HBV DNA was quan-
titated with the ABI 7500 Sequence Detection System
using the HBV RealQuant PCR kit (General Biologicals
Corp.). Briefly, PCR was performed with initial denatur-
ing steps at 50C for 2min and 95C for 10min, followed
by 45 cycles at 95C for 15s and annealing/extending at
58C for 1min.
Validation of the Efficacy of BNE in
HBV-viremia Animals
For drug treatments, SCID mice were divided into five
groups of eight mice each. Each animal was inoculated
with 110
7 cells of HepG2 2.2.15 in 100ml PBS on the
flank subcutaneously; animals in the sham group received
100ml PBS (Fig. 1 shows the experimental protocol).
Tumors were allowed to grow, and blood was withdrawn
on Day 13 prior to drug treatments. For drug treatments,
3TC (13mgkg
1day
1) was given by gavages, and BNE
(195mgkg
1day
1) was administrated to animals via
intraperitoneal and oral routes starting on Day 14 for
10 consecutive days (for both 3TC and BNE). Tumor-
bearing animals that were fed distilled water constituted
the vehicle control group. All animals were sacrificed on
Day 24, and the spleen was taken for NK cell activity
analysis and blood was withdrawn to assess ALT,
HBsAg and HBV DNA as described as earlier. All
animals received human care, and the study protocol
followed the guidelines of the Institutional Animal Care
and Use Committees of the Development Center for
Biotechnology.
Assessment of the NK Cell Activity
The spleen was taken from each drug-treated HBV-
viremia mouse and then homogenized into a single cell
suspension in Hank’s Balanced Salt Solution buffer
(Gibco, USA) by passing through a 40mm diameter
nylon cell strainer (Becton Dickinson, USA). NK cell
activity was measured using the LIVE/DEAD Cell-
Mediated Cytotoxicity kit (Molecular Probes, USA). In
brief, 110
6 YAC-1 cells were pre-labeled with 5ml
3mM DiOC18 fluorescent dye for 2h, and excess dye
was removed by washing with PBS. Then 110
6 of
labeled YAC-1 cells were co-incubated with 210
6
splenocytes for 3h, and 100ml of 3.75mM propidium
iodine dye was added to the reaction at 4C for 20min
avoiding the light. NK cell activity was analyzed by flow
cytometry and was calculated with the equation: NK
activity (%)=viability of treated group (%) – viability of
blank group (%).
Statistical Analysis
Statistical analysis was performed using one-way
ANOVA to analyze variances, and significant differences
were assessed by Dunnett’s test for multiple comparisons.
The paired t-test was used to assess significant differences
before and after treatment in the same individuals.
A P-value of <0.05 was considered statistically significant.
Figure 1. Scheme of the drug treatment protocol used in the HBV-
viremia animal experiments.
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Tumor Formation Caused by HepG2 and HepG2 2.2.15
Cells in SCID Mice
Human hepatoma cells, HepG2 and HepG2 2.2.15, were
implanted subcutaneously into the flank of SCID mice,
and tumor size was measured and calculated in terms of
mass (Fig. 2A). Both hepatoma cells produced tumors of
1130–1250mg within 28 days. The tumor-take rate
of each cell line was 100%. HepG2 2.2.15–derived tumors
grew at a faster rate than HepG2-derived tumors.
Secretion of Serum HBsAg in HepG2 2.2.15
Tumor-bearing Mice
On Days 14 and 28 after tumor cell inoculation, sera
from tumor-bearing mice were collected and analyzed for
HBV DNA and the HBV-related maker, HBsAg. HepG2
2.2.15 tumor-bearing mice had high levels of serum
HBsAg, whereas the HepG2 tumor-bearing mice did not
(HepG2 is a hepatocellular carcinoma without HBV
infection; Fig. 2B).
Production of HBV DNA in Serum from HepG2 2.2.15
Tumor-bearing Mice
To investigate whether the HepG2 2.2.15 cells inoculated
into the SCID mice produced HBV particles in circulat-
ing blood, serum was analyzed for HBV DNA using
quantitative real-time PCR. In the HepG2 2.2.15 group,
the level of serum HBV DNA was 610
4 copies ml
1 on
Day 14 and increased to 1.410
5 copies ml
1 on Day 28
(Fig. 2C). These data indicate that HBV virema was
produced in SCID animals upon injection of HBV-
producing HepG2 2.2.15 cells. Additionally, serum HBV
DNA level was proportional to the size of the HepG2
2.2.15 tumor, thereby simulating the increase in virus
load in chronic hepatitis B patients. These results suggest
that our HepG2 2.2.15 SCID mouse system constitutes
an animal model of HBV-viremia.
Variation in Tumor Weight and Body Weight Among
the Experimental Groups
We used our HBV-viremia model to evaluate the effects
of anti-HBV drugs (see below). In the absence of drugs,
all HepG2 2.2.15 tumor-bearing mice had lower body
weight compared with the sham group (injected with PBS
but no cells) (Fig. 3A). The loss of body weight caused by
HepG2 2.2.15 tumor was associated with tumor forma-
tion. Thus, body weight loss was associated with tumor
formation.
Serum HBsAg and HBV DNA in the HBV-viremia
SCID mice were elevated by Day 13, thus allowing us to
evaluate the anti-HBV efficacy of BNE. HBV-viremia
mice were treated with oral 3TC, oral BNE and
intraperitoneal BNE administration for 10 consecutive
days. Tumor growth in all HBV-viremia animals was not
affected by drug administration (Fig. 3B), suggesting that
Figure 2. Tumor weight, serum HBsAg level and HBV DNA level in the
HBV-viremia animal model. HepG2 or HepG2 2.2.15 cells (10
7) were
inoculated subcutaneously into the flank of SCID mice. (A) Tumor size
was measured every 4 days as shown. Blood was withdrawn from
animals on post-inoculation Days 14 and 28. (B) Serum HBsAg and
(C) serum HBV DNA were measured by ELISA and quantitative
real-time PCR, respectively. Data represent meanSE.
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animal model.
Suppression of Serum HBsAg by 3TC and BNE
Blood was withdrawn from animals when tumor size
reached 400mg on Day 13 and after the 10 consecutive
days of drug treatment that ended on Day 24 (Fig. 1).
After the 10-day treatment with 3TC (by gavage), the
level of HBsAg decreased by 36.1% (Fig. 4A). When
animals were fed BNE by gavage or were injected
intraperitoneally with the same amount of BNE
(195mgkg
1), serum HBsAg level decreased by 32.6%
and 18.4%, respectively. In contrast, serum HBsAg
increased by 19.3% in the vehicle-only control group
fed distilled water. Thus, although the suppression of
HBsAg level was not significant in all treatments, a trend
of serum HBsAg suppression was observed.
Suppression of Serum HBV DNA by 3TC and BNE
Quantitative real-time PCR showed that no serum HBV
DNA was detected in the sham group (Fig. 4B).
However, a 55% increase in HBV DNA level was
observed in the vehicle group (2.7810
5 copies ml
1
on Day 13 to 4.3110
5 copies ml
1 on Day 24), in which
only distilled water was given by gavage during the
10-day period. In the 3TC group, the serum HBV DNA
level was suppressed by 50% from Day 13 to Day 24
(1.6510
6 copies ml
1 to 8.2510
5 copies ml
1). For
the BNE group, BNE administered intraperitoneally sup-
pressed the serum HBV DNA level by 85% (3.4710
6
copies ml
1 to 5.1210
5 copies ml
1) compared with
only 40% for the gavage route (1.6410
6 copies ml
1 to
9.8110
5 copies ml
1).
Figure 4. Effects of BNE on serum HBsAg level and serum HBV DNA
level in HBV-viremia mice. HepG2 2.2.15 cells (10
7) were subcuta-
neously inoculated into the flank of SCID mice. On post-inoculation
Days 13 and 24, blood was withdrawn from drug-treated HBV-viremia
animals, and (A) serum HBsAg level was measured by ELISA, and
(B) serum HBV DNA level was determined by quantitative real-time
PCR. Data represent meanSE *P<0.05 by paired t-test.
***P<0.001 by one-way ANOVA and Dunnett’s test.
Figure 3. Body weight and implanted tumor weight of HBV-viremia
mice. HepG2 2.2.15 cells (10
7) were inoculated subcutaneously into the
flank of SCID mice. (A) Body weight was measured on post-inoculation
Days 13 and 24. (B) HepG2 2.2.15 tumors were excised and weighed
after animals were sacrificed on Day 28. Data represent meanSE.
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To evaluate the biochemical and immunological effects
by BNE, we measured the levels of serum ALT. There
was no significant difference in the serum ALT level of
the sham group between Days 13 and 24 (Fig. 5A).
In contrast, the serum ALT level was elevated in all
HBV-viremia animals, suggesting that these animals
responded biochemically to the implanted tumors.
However, this elevated ALT activity was not suppressed
by 3TC or BNE administration (Fig. 5A).
Inhibition of NK Cell Activity by BNE
To investigate the effect of BNE on innate immunity,
animals were sacrificed and the spleens were taken for
NK cell activity analysis. NK activity was increased by
60% in HBV-viremia animals (the vehicle group) com-
pared to the sham group (no tumor) (Fig. 5B). This
elevated NK activity—set as 100% with respect to the
difference between the sham group and the vehicle group
(distilled water)—was inhibited by 26% by 3TC. NK cell
activity also was inhibited by 31% in animals treated
orally with BNE. Dramatically, NK activity was inhib-
ited by 75% in animals injected intraperitoneally with
BNE (195mg kg
1—the same dose given to the gavage
group), suggesting that intraperitoneally administered
BNE is more effective than by gavage. These data
suggest that serum HBV DNA level is inhibited by BNE,
which in turn results in a decrease in NK activity.
Discussion
Extensive efforts have been put forth in the development
of an HBV animal model to mimic the natural infection
(15). However, these HBV animal models can only
explain a part of the mechanism of anti-HBV drugs;
moreover, the maintenance of animals in these models,
such as HBV transgenic mice (23–25) and the Peking
duck model (26), is very expensive. In this study, we
implanted the HBV-producing cell line, HepG2 2.2.15, in
SCID mice to simulate the phenomenon of HBV viremia,
because viruses generated from HepG2 2.2.15 cells have
been reported to be infectious (27). HBV particles and
HBsAg were detected in the circulation of HepG2 2.2.15
tumor-bearing mice, and the serum HBV DNA level
correlated with tumor growth. Therefore, this HBV-
viremia model might provide information not only on the
absorption, distribution, and metabolism of anti-HBV
drugs but also their efficacy, and these aspects may be
applicable to the treatment of HBV in humans.
Clinical evaluation of the levels of HBsAg, HBeAg
and HBV DNA in serum represents the different stages
of HBV infection (28). Although high levels of serum
HBsAg represent the acute phase of HBV infection, HBV
DNA is one of the most important factors for diagnosis
of different stages of hepatitis B (29). In this study,
elevated serum HBsAg and HBV DNA were detected in
the vehicle group because of HBV production from
HepG2 2.2.15 tumors, and the elevated HBV DNA in
serum was sufficient to allow us to evaluate the anti-HBV
activities of 3TC and BNE. Serum HBsAg and HBV
DNA levels were suppressed by BNE, but tumor growth
was unaffected. BNE caused a decrease in both serum
HBsAg and HBV DNA levels. Furthermore, the intra-
peritoneal administration of BNE was more effective
than by gavage. These findings are consistent with our
previous in vitro study, in which HBV DNA level was
reduced to a greater extent than HBsAg level (13). 3TC
was also effective at suppressing HBV replication
(i.e. 50% reduction in serum HBV DNA level) in
Figure 5. Effects of BNE on the activities of serum ALT and NK cells
in HBV-viremia mice. HepG2 2.2.15 cells (10
7) were subcutaneously
inoculated into the flank of SCID mice. (A) On post-inoculation Days
13 and 24, blood was withdrawn from test animals, and the activity of
serum ALT was measured. (B) On Day 24, drug-treated HBV-viremia
animals were sacrificed and the spleen was homogenized into a single-
cell suspension; the activity of NK cells was subsequently assayed as
described in Subjects and methods section. Data represent meanSE
**P<0.01 by one-way ANOVA and Dunnett’s test.
194 Anti-HBV activity of B. nivea extract in vivoHBV-viremia animals, and this efficacy may improve
with prolonged therapy.
Although SCID mice lack adaptive immunity (functio-
nal T and B cells), they retain innate immunity in C.B17/
icr species (e.g. functional granulocytes and NK cells).
Thus, liver damage that might be caused by adaptive
immunity in normal mice might not be observed in SCID
mice (30). Apparent suppression of NK cell activity was
observed after intraperitoneal administration of BNE.
NK cells play a critical role in host innate defense against
viruses and may be partly responsible for liver injury
resulting from anti-viral responses. However, the exact
role of NK cells in liver injury remains unclear (31).
In this model, the observed increase in ALT level could
not be conclusively attributed to the mouse liver cells or
tumor cells. Nonetheless, histological examination of the
liver of all mice revealed no apparent damage (data not
shown), suggesting that the elevated serum ALT activity
probably was a result of expression from the implanted
tumor cells. Taken together, the data support the anti-
HBV effects of BNE and the chemical composition of
BNE is subject to for further investigation.
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